ABT vs ADPT · P/E 25, rev $44.33B vs rev $142.4M
Abbott Laboratories (ABT) versus Adaptive Biotechnologies Corp (ADPT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Adaptive Biotechnologies Corp (ADPT) is a diagnostics & research company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported ADPT revenue for 2026-06-30 was $142.4M. Net income was -$59.8M. ADPT currently screens at market cap $2.69B.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. ADPT currently screens at market cap $2.69B.
Not investment advice. Open the ABT and ADPT stock pages for the full models.
Not investment advice.